This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

The present invention provides a compound having the structure:

##STR00001##

and use of the compound for inhibiting the growth of or killing

The present invention provides a compound having the structure:

##STR00001##

and use of the compound for inhibiting the growth of or killing

Processes of forming C.sub.sp2C.sub.sp3 bonds at the allylic carbon of a cyclic allylic compound starting material are disclosed, in which a racemic mixture of a cyclic allylic compound having a leaving group attached to the allylic carbon is reacted with a compound having a nucleophilic carbon atom in the presence of a Rh(I), Pd(II) or Cu(I) pre-catalyst and a chiral ligand. The reaction products containing the newly-formed C.sub.sp2C.sub.sp3 bond are generated in high stereoisomeric excess, and may therefore serve as important organic building blocks in the preparation of new agrochemicals and pharmaceuticals.

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

A compound represented by Chemical Formula 1 according to the present invention can coordinate with metal ions to form a bidirectional or multidirectional metal-organic hybrid structure. Thus, the present invention can synthesize various ligands using amine-aldehyde condensation, and synthesize metal-organic materials using the same.

A compound represented by Chemical Formula 1 according to the present invention can coordinate with metal ions to form a bidirectional or multidirectional metal-organic hybrid structure. Thus, the present invention can synthesize various ligands using amine-aldehyde condensation, and synthesize metal-organic materials using the same.

The instant invention relates to compounds of formula I ##STR00001## wherein: R is selected from H, Me or Cl, and R is selected from: H, NH.sub.2, NHCOCH.sub.3 NHCOCF.sub.3 or NHCOCH.sub.2Cl. The invention further provides a process for obtaining the compounds of formula I and their use.

The instant invention relates to compounds of formula I ##STR00001## wherein: R is selected from H, Me or Cl, and R is selected from: H, NH.sub.2, NHCOCH.sub.3 NHCOCF.sub.3 or NHCOCH.sub.2Cl. The invention further provides a process for obtaining the compounds of formula I and their use.